|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-3-6
|
|
pubmed:abstractText |
This multicenter randomized phase III study was designed to compare the efficacy and toxicity of IFN alpha-2c (3.5 MU/d) in combination with either araC (10 mg/m(2) d1-10) or hydroxyurea (HU: 25 mg/kg per day) in newly diagnosed CML patients. A total of 114 patients were randomized. Following a median observation period of 36 (range 1-73) months the major cytogenetic response rates were 25 and 27% and the 4-year survival probabilities 62.5 and 63% for the araC and HU group, respectively. While the overall toxicity profile was comparable between both groups, patients in the HU arm exhibited a slightly higher degree of WHO grades 3 and 4 non-hematological toxicities.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
pubmed-author:AbbrederisKK,
pubmed-author:ApfelbeckUU,
pubmed-author:Austrian CML Study Group,
pubmed-author:BaldingerCC,
pubmed-author:BuderRR,
pubmed-author:BurgstallerSS,
pubmed-author:DubaCC,
pubmed-author:EistererWW,
pubmed-author:FieglMM,
pubmed-author:FridrikMM,
pubmed-author:GastlGG,
pubmed-author:GeisslerDD,
pubmed-author:GreigWW,
pubmed-author:HausmaningerHH,
pubmed-author:HilbeWW,
pubmed-author:KöckLL,
pubmed-author:KührTT,
pubmed-author:KriegerOO,
pubmed-author:LangAA,
pubmed-author:LinWW,
pubmed-author:LinkeschWW,
pubmed-author:LutyEE,
pubmed-author:MichlmayrGG,
pubmed-author:PontJJ,
pubmed-author:SeewannHH,
pubmed-author:ThalerJJ,
pubmed-author:ZaberniggAA
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
405-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12620292-Adult,
pubmed-meshheading:12620292-Aged,
pubmed-meshheading:12620292-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12620292-Cytarabine,
pubmed-meshheading:12620292-Female,
pubmed-meshheading:12620292-Gastrointestinal Diseases,
pubmed-meshheading:12620292-Hematologic Diseases,
pubmed-meshheading:12620292-Humans,
pubmed-meshheading:12620292-Hydroxyurea,
pubmed-meshheading:12620292-Interferon-alpha,
pubmed-meshheading:12620292-Leukemia, Myeloid, Chronic-Phase,
pubmed-meshheading:12620292-Life Tables,
pubmed-meshheading:12620292-Male,
pubmed-meshheading:12620292-Middle Aged,
pubmed-meshheading:12620292-Nervous System Diseases,
pubmed-meshheading:12620292-Recombinant Proteins,
pubmed-meshheading:12620292-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).
|
|
pubmed:affiliation |
Department of Internal Medicine, General Hospital, Grieskirchnerstr. 42, A-4600 Wels, Austria. thomas.kuehr@khwels.at
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
